Cargando…
RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681886/ https://www.ncbi.nlm.nih.gov/pubmed/37864122 http://dx.doi.org/10.1038/s41375-023-02027-3 |
| _version_ | 1785150853996347392 |
|---|---|
| author | O’Sullivan, J. M. Taylor, J. Gerds, A. Buckley, S. Harrison, C. N. Oh, S. List, A. F. Howard, K. Dreau, H. Hamblin, A. Mead, A. J. |
| author_facet | O’Sullivan, J. M. Taylor, J. Gerds, A. Buckley, S. Harrison, C. N. Oh, S. List, A. F. Howard, K. Dreau, H. Hamblin, A. Mead, A. J. |
| author_sort | O’Sullivan, J. M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10681886 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106818862023-11-30 RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort O’Sullivan, J. M. Taylor, J. Gerds, A. Buckley, S. Harrison, C. N. Oh, S. List, A. F. Howard, K. Dreau, H. Hamblin, A. Mead, A. J. Leukemia Letter Nature Publishing Group UK 2023-10-20 2023 /pmc/articles/PMC10681886/ /pubmed/37864122 http://dx.doi.org/10.1038/s41375-023-02027-3 Text en © Crown 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter O’Sullivan, J. M. Taylor, J. Gerds, A. Buckley, S. Harrison, C. N. Oh, S. List, A. F. Howard, K. Dreau, H. Hamblin, A. Mead, A. J. RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort |
| title | RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort |
| title_full | RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort |
| title_fullStr | RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort |
| title_full_unstemmed | RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort |
| title_short | RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort |
| title_sort | ras-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the pac203 cohort |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681886/ https://www.ncbi.nlm.nih.gov/pubmed/37864122 http://dx.doi.org/10.1038/s41375-023-02027-3 |
| work_keys_str_mv | AT osullivanjm raspathwaymutationsarecommoninpatientswithruxolitinibrefractoryintolerantmyelofibrosismolecularanalysisofthepac203cohort AT taylorj raspathwaymutationsarecommoninpatientswithruxolitinibrefractoryintolerantmyelofibrosismolecularanalysisofthepac203cohort AT gerdsa raspathwaymutationsarecommoninpatientswithruxolitinibrefractoryintolerantmyelofibrosismolecularanalysisofthepac203cohort AT buckleys raspathwaymutationsarecommoninpatientswithruxolitinibrefractoryintolerantmyelofibrosismolecularanalysisofthepac203cohort AT harrisoncn raspathwaymutationsarecommoninpatientswithruxolitinibrefractoryintolerantmyelofibrosismolecularanalysisofthepac203cohort AT ohs raspathwaymutationsarecommoninpatientswithruxolitinibrefractoryintolerantmyelofibrosismolecularanalysisofthepac203cohort AT listaf raspathwaymutationsarecommoninpatientswithruxolitinibrefractoryintolerantmyelofibrosismolecularanalysisofthepac203cohort AT howardk raspathwaymutationsarecommoninpatientswithruxolitinibrefractoryintolerantmyelofibrosismolecularanalysisofthepac203cohort AT dreauh raspathwaymutationsarecommoninpatientswithruxolitinibrefractoryintolerantmyelofibrosismolecularanalysisofthepac203cohort AT hamblina raspathwaymutationsarecommoninpatientswithruxolitinibrefractoryintolerantmyelofibrosismolecularanalysisofthepac203cohort AT meadaj raspathwaymutationsarecommoninpatientswithruxolitinibrefractoryintolerantmyelofibrosismolecularanalysisofthepac203cohort |